Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Licensing opportunity from VUFB: alpha2-adrenoceptor antagonist for BPH and heart failure

Feb. 16, 1999

PKC inhibitors designed at Otsuka

Feb. 9, 1999

Alza launches Ditropan XL in the U.S.

Feb. 3, 1999

Chugai patents 2,3-dihydrobenzofurans with cytoprotective effects

Jan. 27, 1999

Oral L-arginine compared to placebo for efficacy in interstitial cystitis

Jan. 25, 1999

Therapeutic advantages of paricalcitol further defined

Jan. 25, 1999

Rochester Medical files PMA for FemSoft

Jan. 22, 1999

Improved treatments for BPH in development at Pfizer

Jan. 22, 1999

SNAP-5540: a uroselective adrenergic BPH agent

Jan. 20, 1999

Ortho-McNeil reports new treatments for BPH

Jan. 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....